Phospho-PTK2 (Y576) Antibody

What is PTK2 (FAK) and what role does phosphorylation at Y576/577 play in cellular signaling?

PTK2, commonly known as focal adhesion kinase (FAK), is a non-receptor protein-tyrosine kinase that plays essential roles in regulating cell migration, adhesion, spreading, actin cytoskeleton reorganization, focal adhesion formation and disassembly, cell cycle progression, proliferation, and apoptosis. This 119.2 kDa protein is ubiquitously expressed but has particularly important functions in epithelial cells, B and T-lymphocytes, and lung fibroblasts .

Phosphorylation at tyrosine residues 576 and 577 occurs within the kinase domain and represents a critical regulatory mechanism for PTK2 activation. The phosphorylation sequence typically follows a specific pattern: Tyr-397 is the major autophosphorylation site that, when phosphorylated, promotes interaction with SRC and SRC family members, which then leads to phosphorylation at Tyr-576 and Tyr-577 . This sequential phosphorylation results in maximal kinase activity of PTK2 and enables the protein to effectively transduce signals downstream.

The biological significance of Y576/577 phosphorylation is substantial, as it is associated with increased cell motility, invasion capability, and enhanced survival signaling pathways . This makes PTK2 phosphorylation a critical event in cancer development and progression, particularly in processes driving tumor growth and metastasis.

How can researchers distinguish between different phosphorylation sites on PTK2 in experimental settings?

Distinguishing between different phosphorylation sites on PTK2 requires careful selection of phospho-specific antibodies and experimental controls. For Y576/577 phosphorylation specifically, researchers should:

• Use validated phospho-specific antibodies: Commercial antibodies such as rabbit polyclonal or monoclonal antibodies against pPTK2-Y576/577 are developed using synthetic phosphorylated peptides around these specific residues (e.g., STYYKA sequence) . These antibodies will not cross-react with other phosphorylation sites like Y397.

• Include phosphatase controls: To confirm specificity, researchers can treat one sample with calf intestinal phosphatase (CIP) as demonstrated in Western blot validations where CIP-treated HepG2 cell lysates show significantly reduced signal compared to untreated samples .

• Use multiple detection methods: While Western blot is the primary method, combining it with ELISA can provide quantitative confirmation of site-specific phosphorylation .

• Employ positive control cell lines: Jurkat and Raji cell lines have been verified as positive controls for pPTK2-Y576/577 detection . For experimental validation, researchers can also use stimulated NIH-3T3 or PC-12 cell lysates, which show increased phosphorylation compared to unstimulated controls .

• Include total PTK2 detection: Always run parallel detection of total PTK2 to normalize phosphorylation levels and ensure changes reflect actual phosphorylation events rather than protein expression differences.

What are the recommended positive control cell lines for Phospho-PTK2 (Y576/577) antibody validation?

Several cell lines have been validated as positive controls for Phospho-PTK2 (Y576/577) antibody testing based on their consistent expression of phosphorylated PTK2:

• Jurkat cells: This human T lymphocyte cell line shows detectable levels of Phospho-PTK2 (Y576/577) and is recommended as a positive control for antibody validation .

• Raji cells: Another hematopoietic cell line (B lymphocyte) that demonstrates PTK2 phosphorylation and can serve as a reliable positive control .

• HepG2 cells: Human hepatocellular carcinoma cells show strong Phospho-PTK2 (Y576/577) signal in Western blot applications, with significant reduction following phosphatase treatment, making them excellent for antibody specificity validation .

• NIH-3T3 cells: These mouse fibroblast cells display regulated PTK2 phosphorylation and are useful for studying stimulation-dependent changes in Y576/577 phosphorylation .

• PC-12 cells: Rat pheochromocytoma cells also demonstrate detectable Phospho-PTK2 (Y576/577) levels and can be used for cross-species validation due to the high conservation of these phosphorylation sites .

For cancer research specifically, the PC-9 and PC-9/PEM (pemetrexed-resistant) non-small cell lung cancer cell lines provide an excellent model system, as PC-9/PEM displays hyperphosphorylation of PTK2 compared to the parental PC-9 line . This comparison can be useful for studying the role of PTK2 phosphorylation in drug resistance mechanisms.

What is the optimal sample preparation protocol for detecting Phospho-PTK2 (Y576/577) by Western blot?

Effective detection of Phospho-PTK2 (Y576/577) requires careful sample preparation to preserve phosphorylation status. Based on validated protocols, the following procedure is recommended:

• Cell lysis buffer composition:

  • Use a buffer containing 1% NP-40 or Triton X-100

  • Include phosphatase inhibitors (sodium orthovanadate, sodium fluoride, and β-glycerophosphate)

  • Add protease inhibitors (PMSF, aprotinin, leupeptin, and pepstatin A)

  • Include 1-2 mM EDTA to chelate metal ions that might activate phosphatases

• Lysis procedure:

  • Wash cells twice with ice-cold PBS

  • Add ice-cold lysis buffer directly to culture plates or cell pellets

  • Incubate on ice for 15-20 minutes with occasional vortexing

  • Centrifuge at 14,000 × g for 15 minutes at 4°C

  • Collect supernatant and determine protein concentration

• Sample preparation:

  • Mix protein lysates with reducing SDS sample buffer

  • Heat samples at 95°C for 5 minutes

  • Load 20-30 μg protein per lane on SDS-PAGE gels (7.5% or 5% gels are optimal for resolving the 119.2 kDa PTK2 protein)

• Electrophoresis and transfer:

  • Run SDS-PAGE at constant voltage (100V) until adequate separation

  • Transfer proteins to PVDF or nitrocellulose membrane at 100V for 90 minutes in cold transfer buffer containing 20% methanol

  • Verify transfer with Ponceau S staining

• Immunoblotting:

  • Block membrane with 5% non-fat milk or 5% BSA in TBS for 1 hour at room temperature

  • Incubate with primary anti-pPTK2-Y576/577 antibody at 1:500-1:2000 dilution overnight at 4°C

  • Wash membrane 3 times with TBST

  • Incubate with HRP-conjugated secondary antibody

  • Develop using enhanced chemiluminescence detection system

This protocol is based on successful detection of phosphorylated PTK2 in multiple cell lines including HepG2, NIH-3T3, and PC-12 .

How can phosphatase inhibition be optimized to maintain PTK2 phosphorylation during experimental procedures?

Preserving phosphorylation status during experimental procedures is critical for accurate analysis of PTK2 Y576/577 phosphorylation. Effective phosphatase inhibition strategies include:

• Comprehensive phosphatase inhibitor cocktail:

  • Sodium orthovanadate (1-2 mM): Inhibits protein tyrosine phosphatases

  • Sodium fluoride (5-10 mM): Blocks serine/threonine phosphatases

  • β-glycerophosphate (10 mM): Inhibits serine/threonine phosphatases

  • Sodium pyrophosphate (2-5 mM): Broad-spectrum phosphatase inhibitor

  • Microcystin-LR (1 μM): Potent inhibitor of PP1 and PP2A phosphatases

• Sample handling precautions:

  • Maintain samples at 4°C throughout all preparation steps

  • Pre-chill all buffers, tubes, and centrifuges

  • Process samples rapidly to minimize time for phosphatase activity

  • Add phosphatase inhibitors fresh to buffers immediately before use

• Validation experiments:

  • Include parallel samples treated with and without phosphatase inhibitors

  • Run phosphatase-treated control samples (e.g., with CIP treatment) to confirm antibody specificity

  • Monitor multiple phosphorylation sites simultaneously (e.g., Y397 and Y576/577) to verify consistent phosphorylation preservation

• Cell stimulation considerations:

  • For maximizing PTK2 phosphorylation, use appropriate stimulation conditions (e.g., integrin engagement, growth factor treatment)

  • Harvest cells at optimal time points post-stimulation for peak phosphorylation levels

  • Verify cell adhesion status, as Tyr-397, Tyr-576, and Ser-722 are phosphorylated only when cells are adherent

• Specialized phosphorylation-preserving protocols:

  • For tissue samples, snap-freeze in liquid nitrogen immediately after collection

  • Consider phospho-protein stabilizing fixatives for immunohistochemistry applications

  • For long-term storage, maintain samples at -80°C with phosphatase inhibitors

The importance of proper phosphatase inhibition is demonstrated in antibody validation studies, where phosphatase treatment significantly reduces or eliminates pPTK2-Y576/577 signal in Western blot applications .

What troubleshooting approaches are recommended for optimizing Phospho-PTK2 (Y576/577) antibody performance?

When working with Phospho-PTK2 (Y576/577) antibodies, researchers may encounter various technical challenges. The following troubleshooting strategies address common issues:

• Weak or no signal:

  • Increase antibody concentration (try 1:500 dilution if 1:2000 shows weak signal)

  • Extend primary antibody incubation time to overnight at 4°C

  • Increase protein loading (30-50 μg per lane)

  • Verify phosphorylation status using positive control lysates (Jurkat or Raji cells)

  • Check cell stimulation conditions that promote PTK2 phosphorylation

  • Ensure complete phosphatase inhibition during sample preparation

• High background or non-specific bands:

  • Optimize blocking conditions (try 5% BSA instead of milk)

  • Increase washing duration and number of washes

  • Dilute primary antibody further (1:1000-1:2000)

  • Reduce secondary antibody concentration

  • Use highly purified antibody preparations (affinity-purified antibodies)

  • Include negative control samples (phosphatase-treated or known negative cell lines)

• Inconsistent results between experiments:

  • Standardize cell culture conditions and passage numbers

  • Prepare fresh lysis buffers with phosphatase inhibitors for each experiment

  • Use consistent protein quantification methods

  • Prepare larger batches of samples for multiple experiments

  • Include normalization controls (total PTK2 and loading controls like β-actin)

• Cross-reactivity concerns:

  • Validate antibody specificity using phosphatase treatment

  • Confirm results with a second antibody targeting the same phosphorylation site

  • Use genetic approaches (PTK2 knockdown or knockout) as negative controls

  • Perform peptide competition assays with phosphorylated and non-phosphorylated peptides

• Detection in different species:

  • Verify antibody cross-reactivity with target species (human, mouse, rat)

  • Adjust antibody concentrations when switching between species

  • Confirm sequence homology of the target phosphorylation region across species

For antibody validation, researchers should test their Phospho-PTK2 (Y576/577) antibodies on parallel samples of untreated and treated cell lysates, as demonstrated in the validation studies with NIH-3T3 and PC-12 cell lines .

How does PTK2 hyperphosphorylation contribute to tyrosine kinase inhibitor resistance in cancer?

PTK2 hyperphosphorylation has emerged as a significant mechanism of resistance to tyrosine kinase inhibitors (TKIs), particularly in EGFR-mutant non-small cell lung cancer (NSCLC). The molecular mechanisms underlying this resistance involve complex signaling pathway alterations:

• Persistent Akt activation: In pemetrexed-resistant NSCLC cell line PC-9/PEM, PTK2 hyperphosphorylation at Y576/577 contributes to constitutive Akt activation, which persists even under EGFR inhibition . This sustained Akt signaling promotes cell survival despite EGFR blockade, effectively bypassing the primary drug target.

• Alternative signaling pathway activation: Hyperphosphorylated PTK2 serves as a node for alternative signaling, allowing cancer cells to maintain proliferation and survival signaling through non-EGFR dependent pathways. This represents a bypass mechanism that circumvents the inhibitory effects of EGFR-TKIs .

• Cell adhesion and survival advantages: PTK2 phosphorylation at Y576/577 enhances cell motility, invasion capability, and survival mechanisms, providing resistant cancer cells with advantages beyond proliferation that contribute to treatment failure and disease progression .

• Widespread occurrence in resistant phenotypes: PTK2 hyperphosphorylation has been observed in various EGFR-TKI-resistant NSCLC models beyond pemetrexed-resistant cells, suggesting it represents a common resistance mechanism rather than a cell line-specific phenomenon .

Experimental evidence supports these mechanisms, as phosphorylation antibody array analysis revealed that PTK2 was significantly hyperphosphorylated in PC-9/PEM cells compared to the parental PC-9 line . Immunoblotting with anti-pPTK2-Y576/577 antibody confirmed this hyperphosphorylation, establishing a clear link between PTK2 phosphorylation status and drug resistance phenotype .

What therapeutic strategies can target PTK2 hyperphosphorylation to overcome drug resistance?

Based on research findings, several therapeutic strategies targeting PTK2 hyperphosphorylation show promise for overcoming drug resistance in cancer:

• Dual inhibition approach: Combining a PTK2 inhibitor (defactinib) with an EGFR-TKI (osimertinib) has demonstrated significant efficacy in restoring drug sensitivity in EGFR-TKI-resistant NSCLC models . This combination therapy effectively overcomes resistance by simultaneously blocking both the primary EGFR target and the bypass PTK2 signaling pathway.

• Mechanism of combination efficacy:

  • Defactinib inhibits phosphorylation at Y576/577 tyrosine residues of PTK2 in a dose-dependent manner

  • This inhibition blocks the downstream Akt activation that normally sustains cancer cell survival

  • Combined with EGFR inhibition, this approach induces apoptosis in previously resistant cells

• In vivo validation: The combination of defactinib and osimertinib has shown improved therapeutic efficacy compared to single-agent treatments in animal models, validating this approach beyond cell culture systems .

• Broader applications: This strategy has demonstrated efficacy in multiple EGFR-TKI-resistant cell lines that exhibit PTK2 hyperphosphorylation, suggesting it may be applicable to various resistance contexts .

• Targeted patient selection: Detecting PTK2 hyperphosphorylation in patient samples could potentially serve as a biomarker for identifying those most likely to benefit from this combination therapy approach.

The research demonstrates that defactinib effectively inhibits PTK2 phosphorylation at Y576/577, and when combined with EGFR-TKI, it restores drug sensitivity by inhibiting Akt and inducing apoptosis in resistant cancer cells . This provides a rational basis for clinical development of combination therapies targeting both EGFR and PTK2 signaling pathways.

What is the relationship between PTK2 Y576/577 phosphorylation and other phosphorylation sites in cancer signaling?

PTK2 contains multiple phosphorylation sites that function in a coordinated manner to regulate its activity and downstream signaling. The relationships between Y576/577 and other phosphorylation sites reveal important regulatory mechanisms in cancer:

• Phosphorylation sequence hierarchy:

  • Tyr-397 is the major autophosphorylation site that initiates PTK2 activation

  • Phosphorylation at Tyr-397 promotes interaction with SRC and SRC family members

  • These interactions lead to secondary phosphorylation events at Tyr-576 and Tyr-577

  • Additional phosphorylation can occur at Tyr-861 and Tyr-925

• Differential regulation of phosphorylation sites:

  • Tyr-397, Tyr-576, and Ser-722 are phosphorylated only when cells are adherent

  • FER promotes phosphorylation at Tyr-577, Tyr-861, and Tyr-925, even when cells are not adherent

  • FGR specifically promotes phosphorylation at Tyr-397 and Tyr-576

• Unique downstream consequences:

  • Phosphorylation at Tyr-397 creates binding sites for interactions with BMX, PIK3R1, and SHC1

  • Phosphorylation at Tyr-925 is important for interaction with GRB2

  • Y576/577 phosphorylation is particularly associated with increased cell motility and invasion

• Dynamic regulation:

  • Dephosphorylation is regulated by phosphatases such as PTPN11

  • PTPN11 is recruited to PTK2 via tyrosine-phosphorylated EPHA2

  • Microtubule-induced dephosphorylation at Tyr-397 is crucial for focal adhesion disassembly

• Implications in cancer signaling:

  • In drug-resistant cancer cells, the balance of phosphorylation/dephosphorylation can be disrupted

  • Hyperphosphorylation at Y576/577 may sustain Akt activation even when upstream signals are blocked

  • The complex interplay between different phosphorylation sites creates opportunities for bypass signaling

Understanding these relationships is critical for developing effective targeting strategies. For example, while defactinib inhibits phosphorylation at Y576/577, its effectiveness may be influenced by the phosphorylation status of other sites, highlighting the importance of comprehensive phosphorylation profiling in research and therapeutic development .

How can researchers quantitatively assess changes in PTK2 Y576/577 phosphorylation in response to experimental treatments?

Quantitative assessment of PTK2 Y576/577 phosphorylation changes requires rigorous experimental approaches and appropriate analytical methods:

• Western blot quantification protocol:

  • Perform standard Western blot using anti-pPTK2-Y576/577 antibodies at optimized dilutions (1:500-1:2000)

  • Run parallel blots for total PTK2 detection

  • Include β-actin or other housekeeping proteins as loading controls

  • Use infrared fluorescence or chemiluminescence detection systems with linear dynamic range

  • Quantify band intensities using software like ImageJ, normalizing phospho-signal to total PTK2 and loading controls

  • Calculate phosphorylation ratio (phospho-PTK2/total PTK2) to determine relative phosphorylation levels

• ELISA-based quantification:

  • Use sandwich ELISA with capture antibodies against total PTK2 and detection antibodies specific for pPTK2-Y576/577

  • Generate standard curves using recombinant phosphorylated PTK2 proteins

  • Normalize results to total protein concentration

  • This approach allows for higher throughput analysis compared to Western blotting

• Phosphorylation array analysis:

  • Phosphorylation array technology can simultaneously measure multiple phosphorylation sites

  • This approach was successfully used to identify PTK2 hyperphosphorylation in PC-9/PEM cells compared to PC-9 cells

  • Arrays provide a broader context of phosphorylation changes across multiple signaling proteins

• Experimental design considerations:

  • Include time-course experiments to capture dynamic phosphorylation changes

  • Test dose-dependent responses to inhibitors like defactinib

  • Include positive controls (stimulated samples) and negative controls (phosphatase-treated samples)

  • Perform biological replicates (minimum n=3) for statistical analysis

• Data analysis and validation:

  • Apply appropriate statistical tests (t-test for simple comparisons, ANOVA for multiple conditions)

  • Validate key findings using complementary techniques (e.g., confirm Western blot results with ELISA)

  • Correlate phosphorylation changes with functional outcomes (e.g., cell migration, invasion, or drug resistance)

In research applications, combining these approaches provides robust quantitative assessment of PTK2 phosphorylation changes. For example, researchers demonstrated that defactinib inhibits PTK2 Y576/577 phosphorylation in a dose-dependent manner, correlating with restoration of drug sensitivity in resistant cancer cells .

How can Phospho-PTK2 (Y576/577) analysis be integrated into personalized cancer treatment strategies?

Phospho-PTK2 (Y576/577) analysis offers significant potential for personalizing cancer treatment approaches through several clinical applications:

• Biomarker for treatment selection:

  • PTK2 hyperphosphorylation status could identify patients likely to benefit from combination therapies targeting both PTK2 and primary oncogenic drivers like EGFR

  • Research shows that EGFR-TKI-resistant NSCLC with PTK2 hyperphosphorylation responds to combination therapy with defactinib and osimertinib

  • This targeted approach could spare patients unlikely to respond from unnecessary treatments and associated toxicities

• Monitoring treatment response:

  • Serial assessment of PTK2 Y576/577 phosphorylation during treatment could provide early indicators of developing resistance

  • Changes in phosphorylation patterns might precede clinical progression, allowing for earlier intervention

  • Adaptive treatment protocols could be developed based on phosphorylation dynamics

• Tissue analysis workflows:

  • Clinical specimens (biopsies or surgical samples) can be processed for phospho-PTK2 analysis

  • Immunohistochemistry protocols using phospho-specific antibodies can be applied to FFPE tissues

  • Phosphorylation can be quantified in fresh frozen tissues using Western blot or ELISA methods

  • Multiplexed analysis combining PTK2 phosphorylation with other biomarkers could enhance predictive power

• Integration with molecular profiling:

  • Combining PTK2 phosphorylation data with genomic profiling (mutations, copy number alterations)

  • Correlating phosphorylation status with transcriptomic signatures

  • Building comprehensive prediction models incorporating multiple data types

• Clinical trial design implications:

  • Patient stratification based on baseline PTK2 phosphorylation status

  • Adaptive trial designs incorporating on-treatment phosphorylation changes

  • Pharmacodynamic endpoints measuring PTK2 inhibition in early-phase trials

The translational potential of this approach is supported by research demonstrating that erlotinib-resistant NSCLC cell lines show PTK2 hyperphosphorylation, and PTK2 inhibition in these models recovers EGFR-TKI sensitivity . This suggests that phospho-PTK2 analysis could identify a subset of resistant cancers amenable to targeted combination strategies.